Last reviewed · How we verify
NCT06135493
Prevention of Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients
Phase 2 trial testing Losartan in Peripheral Neuropathy Due to Chemotherapy in 84 participants. Completed in 30 March 2025.
30 March 2025
Quick facts
| Lead sponsor | Future University in Egypt |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 84 |
| Start date | 12 December 2023 |
| Primary completion | 30 March 2025 |
| Estimated completion | 30 March 2025 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Losartan (losartan) — full drug profile →
Conditions studied
- Peripheral Neuropathy Due to Chemotherapy — all drugs for Peripheral Neuropathy Due to Chemotherapy →
Sponsor
Future University in Egypt
Who can join
18 and older, female only, with Peripheral Neuropathy Due to Chemotherapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Paclitaxel-induced peripheral neuropathy (PIPN) is one of the most dose-limiting side effects; it causes patients discomfort and pain and sometimes causes the termination of the chemotherapy cycles, leading to treatment failure. A lot of interventions have been tried to prevent PIPN, ensure complete administration of the chemotherapy cycles, and increase the survival rate. One of the promising interventions in the prevention of PIPN is Losartan. Losartan is an angiotensin receptor blocker (ARBs) and is used to treat hypertensive patients. There is strong evidence from different preclinical studies and retrospective cohort studies that Losartan has a neuroprotective effect. The purpose of our study is to investigate the efficacy of Losartan in the prevention of peripheral neuropathy associated with Paclitaxel treatment in Breast Cancer patients.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting collagen to optimize cancer immunotherapy.
Wang Y, Zhang F, Qian Z, Jiang Y, et al · · 2025 · cited 7× · PMID 40721833 · DOI 10.1186/s40164-025-00691-y -
The Effect of Losartan in Preventing Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer: A Randomized, Controlled Study.
Mahmoud AMAS, Shash E, Ateyya H, Okasha FA, et al · · 2026 · PMID 41800821 · DOI 10.1002/phar.70124
Verify or expand the search:
- PubMed search for NCT06135493
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Losartan
Trials testing the same drug.
- NCT06491940 — Comparison of the Role of Losartan Alone vs Hydrochlorothiazide Plus Losartan · NA · not yet recruiting
- NCT06333522 — Losartan Use to Mitigate Arthrofibrosis Following Total Joint Arthroplasty · Phase 4 · withdrawn
- NCT06150560 — A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial) · Phase 3 · recruiting
- NCT06108063 — Mitigation of Arthrofibrosis After Total Knee Arthroplasty Using Losartan · Phase 1, PHASE2 · recruiting
- NCT06329050 — The Effects of Losartan on Attention Control: An Eye-tracking Study · NA · recruiting
Other recruiting trials for Peripheral Neuropathy Due to Chemotherapy
Currently open trials in the same condition.
- NCT07423390 — Study on the Efficacy and Safety of Mecobalamin in Preventing Taxane-related Peripheral Neuropathy · Phase 3 · recruiting
- NCT06807294 — Feasibility Testing of a Tai Chi Program for Chemotherapy-Induced Peripheral Neuropathy Treatment (TCT) · NA · recruiting
- NCT06744816 — Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Sin · EARLY_PHASE1 · recruiting
- NCT07167446 — Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy · EARLY_PHASE1 · recruiting
- NCT06616649 — Closed Loop Spinal Cord Stimulation for Chemotherapy Induced Peripheral Neuropathy, a Pilot Study. · NA · recruiting
Other Future University in Egypt trials
Trials by the same sponsor.
- NCT07347925 — Effect of Pre-Hospital ARNI Therapy on Short-Term Outcomes in HFrEF · recruiting
- NCT07129720 — Educational Program to Improve Dental Interns, Knowledge ,Attitude and Awareness Toward Molar Incisor Hypo-mineralizatio · NA · completed
- NCT07193342 — Effect of Computer-controlled vs. Conventional Injection on Pain and Anxiety in Children · NA · completed
- NCT06950762 — Aesthetic Performance of Two Injectable Resin Composites in Class V Cavities: A Randomized Clinical Trial · NA · not yet recruiting
- NCT06882343 — Performance of Bioactive Low Viscosity Composite in Deep Marginal Elevation Restorations · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06135493 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Future University in Egypt
- Last refreshed: 24 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06135493.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing